

August 23rd, 2017

Norwegian Cancer Society invests in Lytix Biopharma, and Lytix strengthens the board with clinical development and commercial oncology experience

Lytix Biopharma is pleased to announce that the Norwegian Cancer Society invested 6 million NOK in the Company as part of the prior private placement of 60 million NOK.

"We are proud that this competent and important institution has invested in Lytix. This as a further confirmation that our drug development within immune-oncology is on the right track, and we greatly appreciate the value of having the Norwegian Cancer Society in place as a significant investor", says Håkan Wickholm, CEO of Lytix Biopharma.

"We have followed Lytix Biopharma closely over some years. Their technology within oncolytic peptides has been evaluated thoroughly. LTX-315 is a very interesting drug candidate and we found the time right to invest in Lytix Biopharma. We hope that the future development can bring clinical benefits for our cancer patients", says Anne Lise Ryel, Secretary General of the Norwegian Cancer Society.

Read Dagens Medisin's article about the Norwegian Cancer Society's investment in Lytix:
www.dagensmedisin.no/artikler/2017/08/22/vil-hjelpe-selskapene-ut-av-dodens-dalnew-page

Edwin Klumper is a life science entrepreneur and combines a scientific and business background. At the general assembly in Lytix June 27th Dr Klumper was elected as a new board member, and last week he attended his first board meeting in Lytix.

Dr Klumper has an MD and a PhD in medicine from VU Academic Medical Center, Amsterdam and an MBA from Rotterdam School of Management, Netherlands. He is co-founder and CEO of iClusion Ltd (an internet platform company recruiting cancer patients for clinical studies), and co-founder and acting CMO of SMS-oncology Ltd (an oncology CRO). Prior he has served as acting CMO at several biotechnology companies, Vice-President Marketing & Sales Europe at Nabi Biopharmaceuticals, European Brand Director at Amgen, Business Unit Director at Amgen in The Netherlands and in the United Kingdom. Cancer research and development is his field of expertise. With 25 years of experience, he has been involved in the European launch of a block buster drug, has successfully turned around a company, and has supervised 80 cancer drug development programs and 20 clinical studies.

For further information, please contact:

Håkan Wickholm (CEO), +46 727 172 526

hakan.wickholm@lytixbiopharma.com

About Lytix Biopharma AS

Lytix Biopharma is a clinical stage biotechnology company focusing on the development of novel immune oncology therapeutics. The lead compound, LTX-315, is a novel first-in-class oncolytic peptide immunotherapy that has demonstrated an ability to induce systemic anticancer immune response. LTX-315, is currently undergoing a Phase 1 trial. The company is privately held and based in Oslo, Norway. Please see www.lytixbiopharma.com